IQ-AI Limited IB's Software featured in award-winning article (6675G)
March 18 2020 - 9:34AM
UK Regulatory
TIDMIQAI
RNS Number : 6675G
IQ-AI Limited
18 March 2020
IQ-AI Ltd
("IQ-AI" or the "Company")
Study Using Imaging Biometrics' Brain Tumor Image Analysis
Software Wins 2019's Top Award from the American Journal of
Neuroradiology
Imaging Biometrics, LLC, (IB), a wholly-owned subsidiary of
IQ-AI and a recognized industry leader in quantitative imaging
analysis for brain tumor diagnosis and treatment, is proud to
announce its software was featured in the top-award-winning article
in the March 2020 issue of the American Journal of Neuroradiology
(AJNR). AJNR, a publication of the American Society of
Neuroradiology, presented the article with the Lucien Levy Award,
recognizing it as the best original research paper accepted in
2019.
The article, "Performance of Standardized Relative CBV for
Quantifying Regional Histologic Tumor Burden in Recurrent
High-Grade Glioma: Comparison against Normalized Relative CBV Using
Image-Localized Stereotactic Biopsies"
(http://www.ajnr.org/content/early/2020/03/12/ajnr.A6486),
showcases a study led by Dr. Leland Hu, MD (Mayo Clinic in Arizona)
that demonstrates the superior ability of IB's vascular mapping
software to identify and distinguish recurrent high-grade brain
tumor from benign treatment effects. These treatment effects occur
frequently in patients undergoing standard chemoradiation treatment
after surgery, and typically resolve over a period of several
months post-treatment. However, these tissues appear similar on
standard MRI creating a major challenge for treating physicians. As
described, IB's exclusive software, which provides a measurement of
tumor burden within each image voxel, addresses this need.
IB's software also streamlines workflow by eliminating
time-consuming manual processing steps, delivering the power of
advanced research analysis in a clinical setting. Dr. Hu's study
demonstrates that IB's image Standardization algorithm is key to
making this possible. Further, the study shows that IB's vascular
mapping is a reliable solution for MR images from multiple
vendors.
"Our relative cerebral blood volume maps have the potential to
aid clinical decision-making before surgery, during recovery, and
during follow-up treatment," said Michael Schmainda, CEO of IB.
"This study not only proves the clinical relevance of vascular
mapping in tumors for monitoring treatment response, it also
highlights the workflow benefits IB provides through automation.
Our solutions are built on decades of specialized experience in
brain tumor imaging, which allows us to create fully automated
methods that are both repeatable and robust. This optimized
workflow certainly has the potential of becoming the consensus
methodology, as the paper cites," Schmainda added.
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Vinod Kaushal/Qu Li
Tel: 020 7469 0930
----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
----------------------------------------------------------
About IQ-AI Ltd (iq-al.ltd) IQ-AI, Ltd, the parent company of
Imaging Biometrics(R) and StoneChecker(TM), is focused on providing
advanced and state-of-the-art medical software and related
services. Imaging Biometrics develops and provides visualization
and analytical solutions enabling clinicians to better diagnose and
treat diseases with greater confidence. Through close collaboration
with researchers and clinicians, sophisticated advancements are
translated into platform-independent software plug-ins which can
extend the base functionality of workstations, imaging systems,
PACS, or medical viewers. By design, IB's advanced visualization
software seamlessly integrates into routine workflows. Please visit
www. imagingbiometrics.com for more information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
STRJPMITMTJBBBM
(END) Dow Jones Newswires
March 18, 2020 10:34 ET (14:34 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From May 2024 to Jun 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Jun 2023 to Jun 2024